Last reviewed · How we verify
NPO Petrovax — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
4 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Longidaza® | Longidaza® | marketed | ||||
| Grippol Quadrivalent | Grippol Quadrivalent | phase 3 | Inactivated influenza vaccine | Immunology / Infectious Disease | ||
| Grippol Plus | Grippol Plus | phase 3 | Inactivated influenza vaccine | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 2
- Other · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Brigham and Women's Hospital · 1 shared drug class
- Chiltern Pesquisa Clinica Ltda · 1 shared drug class
- Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
- Folia Biotech Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Ab&B Bio-tech Co., Ltd.JS · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for NPO Petrovax:
- NPO Petrovax pipeline updates — RSS
- NPO Petrovax pipeline updates — Atom
- NPO Petrovax pipeline updates — JSON
Cite this brief
Drug Landscape (2026). NPO Petrovax — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/npo-petrovax. Accessed 2026-05-16.